73.30SEK+0.14%Mkt Cap: 4.24B SEKP/E: 10.18Last update: 2026-06-01
Linc AB is a private equity and venture capital firm, specializing in early and mature stage investments in pharmaceutical, life-science and med-tech companies. It prefers to invest in drug development usually take place…
Industry Peers
Asset Management363.02BSEKP/E 46.5
220.70BSEKP/E 5.5
216.45BSEKP/E 5.4
158.99BUSDP/E 25.7
144.53BUSDP/E 30.3
89.00BUSDP/E 32.5
75.08BUSDP/E 81.4
44.10BUSDP/E 16.2
Indicators:|
Key Statistics
Company
Market Cap4.24B SEK
Enterprise Value4.01B SEK
Revenue (TTM)437.99M SEK
Gross Profit-1.59M SEK
Net Income (TTM)-399.65M SEK
Revenue/Share7.563 SEK
Last Price73.30 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees2
CountrySE
SectorFinancial Services
IndustryAsset Management
ISINSE0015949433
Valuation
P/E (Trailing)10.18
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue9.14
P/S9.68
P/B0.96
EPS (TTM)7.20
EPS (Forward)—
52W Range
58.9058% of range83.60
52W High83.60 SEK
52W Low58.90 SEK
Profitability
Gross Margin-31.82%
Oper. Margin102.03%
EBITDA Margin0.00%
Profit Margin-7992.94%
ROE-9.02%
ROA-9.00%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-265.68M SEK
CapEx (TTM)—
FCF Margin59.77%
FCF Yield6.17%
Net Debt-234.02M SEK
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio37.07
Quick Ratio34.64
Book Value/Sh76.52 SEK
Cash/Share4.041 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)71.00 SEK
Target Range71.00 SEK – 71.00 SEK
# Analysts1
Ownership
Shares Out.57.91M
Float22.17M
Insiders63.36%
Institutions23.82%
Technical
SMA 5073.03 (+0.4%)
SMA 20070.47 (+4.0%)
Beta0.71
S&P 52W Chg27.70%
Avg Vol (30d)41.31K
Avg Vol (10d)40.20K
Technical Indicators
RSI (14)47.6
MACD0.6476
MACD Signal0.6086
MACD Hist.+0.0390
BB Upper77.06 SEK
BB Middle73.82 SEK
BB Lower70.58 SEK
BB Width8.77%
ATR (14)1.901 SEK
Vol Ratio (20d)1.02x